More Financing for Device That Lowers Eye Pressure

Ivantis, developer of the Hydrus Microstent device designed to lower eye pressure for glaucoma patients, reportedly has secured an additional $14 million from Vertex Ventures and GBS Ventures in the final close of its Series B financing. The funds will support three ongoing clinical trials, including the US pivotal trial. Ivantis also has received approval from the FDA to move from the initial safety phase of its US pivotal trial to the expanded phase. Additionally, the company announced that it recently presented two-year data from international trials on the Hydrus device at the American Academy of Ophthalmology. Read more.